title: Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
abstract: The aim of this paper was to review the up-to-date evidence base on pharmacology and clinical properties of lurasidone. Lurasidone is an atypical antipsychotic, approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia and bipolar depression. Lurasidone exhibits both an antipsychotic and antidepressant action. Based on its pharmacodynamics profile, it is believed that the drug's clinical action is mediated mainly through the D2, 5-HT2A and 5-HT7 receptors inhibition. In patients with schizophrenia the recommended dose range is 40-80mg/day. In bipolar depression broader dosage ranges (20-120mg/day) were found to be effective. In terms of side effects, higher rates of akathisia, parkinsonism and hyperprolactinemia were observed in individuals receiving lurasidone (as compared to patients treated with other atypical antipsychotics). On the other hand, treatment with lurasidone yields relatively lower risk for developing sedation or overweight/obesity.
authors.affiliation: Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kraków, Poland. Electronic address: rafal.jaeschke@gmail.com.
authors.forename: Rafał R
authors.initials: RR
authors.lastname: Jaeschke
authors.affiliation: Department of Neurobiology, Laboratory of Trace Elements Neurobiology, Institute of Pharmacology, Polish Academy of Science, Kraków, Poland. Electronic address: sowa@if-pan.krakow.pl.
authors.forename: Magdalena
authors.initials: M
authors.lastname: Sowa-Kućma
authors.affiliation: Department of Neurobiology, Laboratory of Trace Elements Neurobiology, Institute of Pharmacology, Polish Academy of Science, Kraków, Poland.
authors.forename: Patrycja
authors.initials: P
authors.lastname: Pańczyszyn-Trzewik
authors.affiliation: Department of Neurobiology, Laboratory of Trace Elements Neurobiology, Institute of Pharmacology, Polish Academy of Science, Kraków, Poland.
authors.forename: Paulina
authors.initials: P
authors.lastname: Misztak
authors.affiliation: Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kraków, Poland.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Styczeń
authors.affiliation: Department of Affective Disorders, Chair of Psychiatry, Jagiellonian University Medical College, Kraków, Poland.
authors.forename: Wojciech
authors.initials: W
authors.lastname: Datka
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D006801:Humans; D006966:Hyperprolactinemia / Q000139:chemically induced; D000069056:Lurasidone Hydrochloride / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D011869:Radioligand Assay; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D000069056:Lurasidone Hydrochloride
keywords: Atypical antipsychotics; Bipolar disorder; Lurasidone; Schizophrenia